Immatics Appoints Biotech Executive Eliot Forster to Board of Directors
September 15 2020 - 7:00AM
Tuebingen, Germany and Houston, Texas,
September 15, 2020 – Immatics N.V.
(NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical
company active in the discovery and development of T cell
redirecting cancer immunotherapies, announced today the appointment
of Eliot Forster, PhD, to its Board of Directors. Forster currently
serves as Chief Executive Officer (CEO) at bispecific antibody
developer, F-star Therapeutics, and Non-Executive Chairman of
Avacta plc. He brings to Immatics extensive experience, including
leadership of trailblazing biopharmaceutical companies in the field
of immuno-oncology and others. He will further strengthen Immatics’
Board as the company develops its pipeline of T cell receptor
(TCR)-based therapeutics.
Peter Chambré, Chairman of Immatics’ Board of
Directors commented: “Being able to attract Eliot to the Board is a
testament to the transformational science and corporate culture
that Immatics has established and the momentum the Company has
gained towards bringing the power of T cells to cancer patients. We
are delighted to have Eliot join our Board and look forward to his
counsel as we continue implementing strategies to achieve our
clinical milestones and Immatics’ next development steps.”
Eliot Forster added: “At a time when cancer
immunotherapies hold such great promise for the future, Immatics
has developed a powerful approach to discover and address novel
cancer targets previously inaccessible by current immuno-oncology
therapies. The company’s broad pipeline, which includes TCR product
candidates that can target tumor cells but also the
microenvironment, has the potential to transform the landscape of
TCR-based treatments. I am thrilled to be joining the Board of
Immatics, a company that I have watched and admired for a long
time. I am looking forward to working with the Board, as well as
Harpreet and the team to develop the company’s T cell technology,
to transform the lives of patients with cancer.”
Eliot Forster joined F-star Therapeutics in 2018
and under his leadership significantly increased its portfolio of
immuno-oncology products and will list the company on Nasdaq
through a recently announced combination with Spring Bank
Pharmaceuticals Inc. Before joining F-star, Eliot Forster served as
CEO of Immunocore. During his tenure he was responsible for raising
considerable capital and steering the company’s strategy in
immuno-oncology, infectious diseases and autoimmune diseases, as
well as establishing clinical collaborations with global
pharmaceutical companies. Prior to this, he was the CEO of
Creabilis Therapeutics and Solace Pharmaceuticals Inc. Forster’s
other previous positions include Head of Development and Operations
for the EU and Asia at Pfizer and founding Chairman of MedCity.
Forster holds a PhD in neurophysiology from Liverpool University
and an MBA from Henley Management College.
Notes to Editors
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
For regular updates about Immatics, visit
www.immatics.com. You can also follow us on Twitter and
LinkedIn.
Forward-Looking
Statements:Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
timing of product candidates and Immatics’ focus on partnerships to
advance its strategy are forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“may”, “should”, “expect”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the Securities and Exchange Commission (SEC).
Nothing in this presentation should be regarded as a representation
by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such
forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as
of the date they are made. Immatics undertakes no duty to update
these forward-looking statements.
For more information, please
contact:
For media enquiries |
Investor
Relations Contact |
Gretchen Schweitzer or Jacob Verghese, PhD |
John
Graziano |
Trophic Communications |
Solebury
Trout |
Phone: +49 89 2388 7731 |
Phone: +1
646-378-2942 |
immatics@trophic.eu |
jgraziano@soleburytrout.com |
|
|
Immatics N.V. |
|
Anja Heuer |
Jordan
Silverstein |
Corporate Communications |
Head of
Strategy |
Phone: +49 89 540415-606 |
Phone: +1
281-810-7545 |
media@immatics.com |
InvestorRelations@immatics.com |
- New Board Member_ENG
- New Board Member_GER
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024